ABcann Global (TSXV: ABCN) (OTC: ABCCF) - Investor Dashboard


➔ ABcann Global
TSXV Ticker: ABCN
OTC Ticker: ABCCF
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees:  34
Established: 2012
CEO: Barry Fishman

Abcann Global – Management Team


Ken Clement – Founder, Executive Chairman

Ken has been the key component and driving force behind ABcann’s development. His vison is unique in the medical cannabis sector with the concept of standardized production and dosage. Ken enjoys a strong rapport with Health Canada and numerous strategic partnerships worldwide. “I have only met briefly with Ken but anyone who is able to take an idea and with Pitbull determination transform it into a world class corporation like ABcann, in such a short time, is truly a miracle worker.” Dr. Mike Shannon, former Deputy Surgeon General Canada.

Barry Fishman – Chief Executive Officer

Mr. Fishman has almost 20 years of experience as a business leader, most recently as CEO of international specialty pharmaceutical company Merus Labs (TSX:MSL) (NASDAQ:MSLI). Under his leadership, sales and EBITDA grew at a compound annual growth rate above 50%, culminating in the acquisition of Merus by Norgine B.V. in July, 2017 for approximately $342 million. He also has several years of experience serving as a director of public companies in the cannabis sector. Mr. Fishman previously served as CEO of both Teva Canada and Taro Canada, and is a past Chair of the Canadian Generic Manufacturers Association. He began his pharmaceutical career at Eli Lilly, where he advanced through several cross-functional leadership roles, including Vice President of Marketing.

Jenny Guan – CFO

Jenny has been with ABcann since 2012 and is responsible for corporate financial reporting, operations, treasury, tax, budget planning, corporate policies, internal controls and ABcann’s relationship with external auditors. Coming from a business accounting background, she has over 15 years experience in various key leadership roles in business operations, finance, and program management.

Andrew LaCroix – VP, Business Development, Director

Andrew LaCroix started his legal career working for blue chip firms in Vancouver, and has run his own practice on Vancouver Island since 2008. Andrew has been involved with ABcann since its inception as general counsel, drafting and submitting ABcann’s initial Health Canada license application and acting as general counsel on a host of different business and legal issues. Andrew will provide ABcann Global Corporation with ongoing advice, and play a large role in both domestic and international business development.

Neil Kapp – President, Operations

Neil has over 30 years of experience in operating and managing businesses, in both the commercial development and recreational facilities market place, with annual revenues in excess of $6.5M. Neil serves as managing partner and CFO for this group of companies, which has over 200 employees.

John Molloy – Executive Consultant

Former President and CEO of PARTEQ Innovations at Queen’s University for 28 years. His leadership led to the formation of 48 companies based on Queen’s research, with more than $1.7 billion invested to date in those companies.

Aaron Keay – Director

Aaron has spent the last 11 years working in the capital markets across a broad spectrum of sectors. Aaron’s roles have ranged from corporate finance, senior management and board member. He has overseen finance and M&A transactions and Capital raising, helping private companies navigate from the private to public markets. His work and leadership has helped raise ~$250m for public and private market issuers.

Daryl Kramp – Director

daryl-kramp-abcannWas the Member of Parliament for the riding of Prince Edward-Hastings from 2004 through October of 2015. His past political experience includes six years as a municipal councilor and deputy reeve in the municipality of Madoc. Mr. Kramp brought vast experience in the private sector to his role. He has created and operated several successful business ventures in the fields of retail, wholesale and hospitality.

John Easson – Director

john-easson-abcannJohn has over 23 years of experience advising companies on Corporate Finance, and Mergers and Acquisition transactions. Whether it be through his own BE Capital Advisors practice or his 15 years working for BMO, RBC and Scotiabank, John has significant transaction experience with a range of companies from small private start-ups to some of Canada’s largest public companies.

Paul Lucas – Director

paul-lucas-abcannMr. Lucas served as President and CEO of GlaxoSmithKline Canada from 1994 until he retired in 2012. Currently Mr. Lucas is a member of the Board of Directors of RnA Diagnostics Inc and He is also Chair of the Board of EcoSynthetix Inc., Induran Ventures Inc., and Life Sciences Ontario. He received his BSc (Honours) in Biology and Chemistry from Queen’s University, and obtained his Chartered Directors designation (CDir) from the Directors College.

Significant Insider Ownership


Ken Clement, Founder & Executive Chairman
36.23mm shares

Barry Fishman, CEO
1.125mm shares and 1.25mm options

Jenny Guan, CFO
11.07mm shares

Neil Kapp, COO
1.51mmmm shares

Andrew LaCroix, Director and VP
1.23mm shares

Aaron Keay, Director
1.1mm shares

Paul Lucas, Director
310K shares


Visit ABcann Global, Inc.
at www.abcannglobal.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. ABcann Global, Inc. is a client of NCV Media, LLC. Read our full disclaimer.